Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

NCT04811131 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

114

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Vitiligo

Interventions

DRUG: ARQ-252 cream 0.3%
DRUG: ARQ-252 Vehicle cream
DEVICE: NB-UVB phototherapy active treatment
DEVICE: NB-UVB phototherapy sham treatment

Sponsor

Arcutis Biotherapeutics, Inc.